Polypharmacy and the Clinical Inertia Conundrum for GDMT

JACC Heart Fail. 2023 Nov;11(11):1518-1520. doi: 10.1016/j.jchf.2023.08.015. Epub 2023 Sep 27.

Authors

Robert L Page 2nd¹, Sheryl L Chow²

Affiliations

¹ Department of Clinical Pharmacy, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
² Department of Pharmacy Practice and Administration, Western University of Health Sciences, College of Pharmacy, Pomona, California, USA; Department of Medicine, Division of Cardiology, University of California, Irvine Medical Center, Orange, California, USA. Electronic address: SChow@westernu.edu.

PMID: 37768247
DOI: 10.1016/j.jchf.2023.08.015

No abstract available

Keywords: clinical inertia; guideline-directed medical therapy; polypharmacy.

Publication types

Editorial
Comment

MeSH terms

Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Heart Failure* / drug therapy
Humans
Polypharmacy*
Stroke Volume
Treatment Outcome

Substances

Angiotensin-Converting Enzyme Inhibitors